Search for content, post, videos

Valo Therapeutics acquires PeptiCHIP technology

business deal
Valo Therapeutics has announced the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.